5-FU is rapidly metabolized in the liver, with dihydropyrimidine dehydrogenase (DPD) being the rate-limiting enzyme. 5-Fluorouracil (5-FU) is widely and successfully used for the treatment of solid tumors. In some patients, however, an enzyme variant results in the need of therapy adjustment. The majority of the 3 to 5% of patients not adequately metabolizing 5-fluorouracil (5-FU) carry a specific mutation in their DPYD gene. While heterozygous patients should be given lower 5-FU doses, homozygous patients should receive alternative chemotherapeutic treatment. Identification of the relevant mutation in DPD and determination of whether a carrier is homozygous or heterozygous for this DPD mutation is crucial for allowing an adequate 5-FU therapy. 5FU StripAssay
The PGX-5FU StripAssay identifies the most common mutation with therapeutic relevance for 5-FU treatment.
The ViennaLab PGX-5FU StripAssays®
• are based on reverse-hybridization of biotinylated PCR products
• combine probes for mutations and controls in a parallel array of allele-specific oligonucleotides
• work with immobilized oligos on a teststrip
• show mutations by enzymatic color reaction easily visible to the naked eye
|StripAssay®||Gene||SNP||FCGR 5-670||PGX-5FU 4-720|